Isoniazid Mediates the CYP2B6*6 Genotype-Dependent Interaction between Efavirenz and Antituberculosis Drug Therapy through Mechanism-Based Inactivation of CYP2A6

Efavirenz is commonly used to treat patients coinfected with human immunodeficiency virus and tuberculosis. Previous clinical studies have observed paradoxically elevated efavirenz plasma concentrations in patients with the CYP2B6*6/*6 genotype (but not the CYP2B6*1/*1 genotype) during coadministrat...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Court, Michael H., Almutairi, Fawziah E., Greenblatt, David J., Hazarika, Suwagmani, Sheng, Hongyan, Klein, Kathrin, Zanger, Ulrich M., Bourgea, Joanne, Patten, Christopher J., Kwara, Awewura
Formato: Artigo
Idioma:Inglês
Publicado: American Society for Microbiology 2014
Assuntos:
Pharmacology
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4068589/
https://ncbi.nlm.nih.gov/pubmed/24820076
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.02532-14
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares